Arcus Biosciences, Inc. (RCUS)Healthcare | Biotechnology | Hayward, United States | NYSE
24.28 USD
+0.69
(2.925%)
⇧
(April 17, 2026, 3:38 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:25 p.m. EDT
RCUS appears to be in a volatile and uncertain phase, with mixed signals from both the fundamentals and options market. The recent news highlights some positive developments, but the company is still in a loss-making position with negative profit margins and a high debt-to-equity ratio. The short-term price forecast shows a slight downward trend, and the options data indicates a cautious approach from traders. While there may be opportunities for short-term traders looking to capitalize on volatility, long-term investors should approach with caution due to the company's financial risks and uncertain future. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.066356 |
| AutoTheta | 0.067693 |
| AutoETS | 0.067708 |
| AutoARIMA | 0.067713 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.643 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 34.707 |
| Revenue per Share | 2.3 |
| Market Cap | 3,043,485,184 |
| Forward P/E | -6.96 |
| Beta | 0.86 |
| Profit Margins | -142.91% |
| Website | https://arcusbio.com |
As of April 11, 2026, 1:25 p.m. EDT: Options speculators are showing mixed signals. The calls show a concentration of open interest (OI) around the $22.5 strike, indicating some bullish sentiment, but the puts also show significant OI at strikes below the current price, suggesting caution or bearishness. The high IV (implied volatility) on puts, especially at lower strikes, indicates potential for downside risk. The overall options activity suggests a wait-and-see attitude, with traders possibly hedging against volatility or anticipating a directional move.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0596628 |
| Address1 | 3,928 Point Eden Way |
| All Time High | 49.1 |
| All Time Low | 6.3 |
| Ask | 24.28 |
| Ask Size | 300 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 830,420 |
| Average Daily Volume3 Month | 1,095,027 |
| Average Volume | 1,095,027 |
| Average Volume10Days | 830,420 |
| Beta | 0.859 |
| Bid | 24.25 |
| Bid Size | 200 |
| Board Risk | 10 |
| Book Value | 5.036 |
| City | Hayward |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.28 |
| Current Ratio | 4.359 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 24.34 |
| Day Low | 23.57 |
| Debt To Equity | 34.707 |
| Display Name | Arcus Biosciences |
| Earnings Call Timestamp End | 1,772,055,000 |
| Earnings Call Timestamp Start | 1,772,055,000 |
| Earnings Timestamp | 1,772,053,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -376,000,000 |
| Ebitda Margins | -1.5222701 |
| Enterprise To Ebitda | -5.838 |
| Enterprise To Revenue | 8.887 |
| Enterprise Value | 2,194,994,176 |
| Eps Current Year | -3.65 |
| Eps Forward | -3.49 |
| Eps Trailing Twelve Months | -3.29 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.5852 |
| Fifty Day Average Change | 2.6948013 |
| Fifty Day Average Change Percent | 0.124844864 |
| Fifty Two Week Change Percent | 205.96628 |
| Fifty Two Week High | 26.4 |
| Fifty Two Week High Change | -2.119999 |
| Fifty Two Week High Change Percent | -0.08030299 |
| Fifty Two Week Low | 7.06 |
| Fifty Two Week Low Change | 17.220001 |
| Fifty Two Week Low Change Percent | 2.4390936 |
| Fifty Two Week Range | 7.06 - 26.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,521,120,600,000 |
| Float Shares | 88,653,417 |
| Forward Eps | -3.49 |
| Forward P E | -6.9570203 |
| Free Cashflow | -162,250,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 601 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -1.11741 |
| Gross Profits | -276,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29488 |
| Held Percent Institutions | 0.74504 |
| Implied Shares Outstanding | 125,349,476 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. |
| Long Name | Arcus Biosciences, Inc. |
| Market | us_market |
| Market Cap | 3,043,485,184 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_325435188 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -353,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,956,994,138 |
| Number Of Analyst Opinions | 10 |
| Open | 24.12 |
| Operating Cashflow | -482,000,000 |
| Operating Margins | -3.4545498 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 510 694 6200 |
| Previous Close | 23.59 |
| Price Eps Current Year | -6.652055 |
| Price Hint | 2 |
| Price To Book | 4.821287 |
| Price To Sales Trailing12 Months | 12.321802 |
| Profit Margins | -1.42915 |
| Quick Ratio | 4.316 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.69000053 |
| Regular Market Change Percent | 2.9249704 |
| Regular Market Day High | 24.34 |
| Regular Market Day Low | 23.57 |
| Regular Market Day Range | 23.57 - 24.34 |
| Regular Market Open | 24.12 |
| Regular Market Previous Close | 23.59 |
| Regular Market Price | 24.28 |
| Regular Market Time | 1,776,454,728 |
| Regular Market Volume | 429,798 |
| Return On Assets | -0.21079001 |
| Return On Equity | -0.63262004 |
| Revenue Growth | 0.269 |
| Revenue Per Share | 2.3 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 125,349,476 |
| Shares Percent Shares Out | 0.0788 |
| Shares Short | 9,876,250 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,265,210 |
| Short Name | Arcus Biosciences, Inc. |
| Short Percent Of Float | 0.1116 |
| Short Ratio | 7.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | RCUS |
| Target High Price | 49.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 34.2 |
| Target Median Price | 31.0 |
| Total Cash | 981,000,000 |
| Total Cash Per Share | 7.826 |
| Total Debt | 219,000,000 |
| Total Revenue | 247,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.6934 |
| Two Hundred Day Average Change | 6.5866013 |
| Two Hundred Day Average Change Percent | 0.3722632 |
| Type Disp | Equity |
| Volume | 429,798 |
| Website | https://arcusbio.com |
| Zip | 94,545 |